Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4917MR)

This product GTTS-WQ4917MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4917MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8082MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ13075MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ274MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ8616MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ13019MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10183MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13266MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ12297MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW